Exhibit 99.3

ASML — Summary IFRS Consolidated Income Statements ^1,2

	Three months ended,						Nine months ended,
(in thousands EUR)	Sep 30, 2007			Sep 28, 2008			Sep 30, 2007			Sep 28, 2008
Net system sales		843,232			590,723			2,516,425			2,136,296
Net service and field option sales		91,142			105,770			296,842			323,562
Total net sales		934,374			696,493			2,813,267			2,459,858
Cost of sales		581,839			452,713			1,735,058			1,539,628
Gross profit on sales		352,535			243,780			1,078,209			920,230
Research and development costs, net of credits		76,886			88,571			268,236			258,360
Selling, general and administrative costs		55,977			52,245			168,449			165,272
Operating income		219,672			102,964			641,524			496,598
Interest income		9,089			6,599			21,571			15,147
Income before income taxes		228,761			109,563			663,095			511,745
Provision for income taxes		(54,873	)		(27,013	)		(169,076	)		(52,244	)
Net income		173,888			82,550			494,019			459,501

ASML — Summary IFRS Consolidated Balance Sheets ^1,2

(in thousands EUR)	Dec 31, 2007		Sep 28, 2008
ASSETS
Property, plant and equipment		380,894		503,057
Goodwill		136,246		137,273
Other intangible assets		216,908		281,323
Deferred tax assets		220,863		228,605
Derivative financial instruments		20,930		12,297
Other non-current assets		32,828		32,607
Total non-current assets		1,008,669		1,195,162
Inventories		1,102,210		1,134,039
Derivative financial instruments		12,319		20,953
Accounts receivable, net		637,975		574,230
Other current assets		193,415		210,579
Cash and cash equivalents		1,271,636		1,312,993
Total current assets		3,217,555		3,252,794
Total assets		4,226,224		4,447,956
EQUITY AND LIABILITIES
Equity		2,039,011		2,314,693
Other long-term debt		595,783		590,971
Derivative financial instruments		—		891
Deferred tax and other liabilities		257,325		256,866
Other deferred liabilities		7,935		7,859
Total non-current liabilities		861,043		856,587
Accounts payable		282,953		270,932
Accrued liabilities and other		927,841		948,139
Current tax liabilities		104,095		42,395
Derivative financial instruments		11,281		15,210
Total current liabilities		1,326,170		1,276,676
Total equity and liabilities		4,226,224		4,447,956

ASML — Summary IFRS Consolidated Statements of Cash Flows ^1,2

	Three months ended,						Nine months ended,
(in thousands EUR)	Sep 30, 2007			Sep 28, 2008			Sep 30, 2007			Sep 28, 2008
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		173,888			82,550			494,019			459,501
Depreciation and amortization		58,330			50,662			161,211			142,247
Disposals of property, plant and equipment		1,698			1,413			12,572			3,827
Share-based payments		3,675			3,581			10,342			9,858
Change in tax assets and liabilities		3,928			2,242			28,486			(70,426	)
Change in assets and liabilities		(6,268	)		(80,071	)		6,342			7,279
Net cash provided by operating activities		235,251			60,377			712,972			552,286
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(49,676	)		(68,237	)		(125,188	)		(188,711	)
Proceeds from sale of property, plant and equipment		—			—			3,355			—
Purchases of intangible assets		(60,659	)		(41,502	)		(96,138	)		(130,111	)
Acquisition of subsidiary (net of cash acquired)		—			—			(188,011	)		—
Net cash used in investing activities		(110,335	)		(109,739	)		(405,982	)		(318,822	)
CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of shares in conjunction with conversion rights of bond holders and stock options		—			—			(156,253	)		(87,603	)
Dividend paid		—			(394	)		—			(107,841	)
Net proceeds from issuance of shares and stock options		25,428			1,439			51,825			4,967
Net proceeds from issuance of bonds		—			—			593,790			—
Redemption and/or repayment of debt		(1,530	)		(1,280	)		(1,875	)		(1,280	)
Net cash provided by (used in) financing activities		23,898			(235	)		487,487			(191,757	)
Net cash flows		148,814			(49,597	)		794,477			41,707
Effect of changes in exchange rates on cash		(2,846	)		1,692			(5,107	)		(350	)
Net increase (decrease) in cash & cash equivalents		145,968			(47,905	)		789,370			41,357

ASML — Quarterly Summary IFRS Consolidated Income Statements ^1,2

	Three months ended,
	Sep 30,			Dec 31,			Mar 30,			Jun 29,		Sep 28,
(in millions EUR)	2007			2007			2008			2008		2008
Net system sales		843.2			834.9			820.0			725.6		590.7
Net service and field option sales		91.2			120.0			99.2			118.6		105.8
Total net sales		934.4			954.9			919.2			844.2		696.5
Cost of sales		581.9			583.7			561.7			525.3		452.7
Gross profit on sales		352.5			371.2			357.5			318.9		243.8
Research and development costs, net of credits		76.8			84.7			82.7			87.1		88.6
Selling, general and administrative costs		56.0			73.5			57.7			55.3		52.2
Operating income		219.7			213.0			217.1			176.5		103.0
Interest income (charges)		9.1			(2.2	)		3.6			5.0		6.6
Income before income taxes		228.8			210.8			220.7			181.5		109.6
Benefit from (provision for) income taxes		(54.9	)		18.5			(54.2	)		29.0		(27.0	)
Net income		173.9			229.3			166.5			210.5		82.6

ASML — Summary IFRS Consolidated Balance Sheets ^1,2

	Sep 30,		Dec 31,		Mar 30,		Jun 29,		Sep 28,
(in millions EUR)	2007		2007		2008		2008		2008
ASSETS
Property, plant and equipment		343.3		380.9		401.4		458.1		503.1
Goodwill		141.7		136.3		127.2		127.3		137.3
Other intangible assets		198.4		216.9		238.0		260.5		281.3
Deferred tax assets		252.3		220.9		213.3		238.4		228.6
Derivative financial instruments		9.9		20.9		47.7		1.4		12.3
Other non-current assets		33.3		32.8		31.8		32.0		32.6
Total non-current assets		978.9		1,008.7		1,059.4		1,117.7		1,195.2
Inventories		1,021.2		1,102.2		1,152.0		1,130.2		1,134.0
Derivative financial instruments		23.5		12.3		36.5		46.6		21.0
Accounts receivable, net		611.7		638.0		741.5		516.9		574.2
Other current assets		211.8		193.4		202.4		185.9		210.6
Cash and cash equivalents		2,445.2		1,271.6		1,397.1		1,360.9		1,313.0
Total current assets		4,313.4		3,217.5		3,529.5		3,240.5		3,252.8
Total assets		5,292.3		4,226.2		4,588.9		4,358.2		4,448.0
EQUITY AND LIABILITIES
Equity		1,961.8		2,039.0		2,121.8		2,242.6		2,314.7
Convertible subordinated debt		40.1		—		—		—		—
Other long-term debt		597.8		595.8		609.1		585.6		591.0
Derivative financial instruments		0.7		—		—		11.2		0.9
Deferred tax and other liabilities		259.3		257.3		282.9		260.2		256.9
Other deferred liabilities		8.2		7.9		7.2		7.4		7.8
Total non-current liabilities		906.1		861.0		899.2		864.4		856.6
Accounts payable		320.9		283.0		479.6		267.2		271.0
Accrued liabilities and other		1,933.0		927.8		957.7		910.8		948.1
Current tax liabilities		151.9		104.1		111.5		50.8		42.4
Derivative financial instruments		18.6		11.3		19.1		22.4		15.2
Total current liabilities		2,424.4		1,326.2		1,567.9		1,251.2		1,276.7
Total equity and liabilities		5,292.3		4,226.2		4,588.9		4,358.2		4,448.0

ASML — Summary IFRS Consolidated Statements of Cash Flows ^1,2

	Three months ended,
	Sep 30,			Dec 31,			Mar 30,			Jun 29,			Sep 28,
(in millions EUR)	2007			2007			2008			2008			2008
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		173.9			229.3			166.5			210.5			82.6
Depreciation and amortization		58.3			49.2			46.8			44.8			50.7
Disposals of property, plant and equipment		1.7			1.6			1.1			1.3			1.4
Share-based payments		3.7			6.8			3.4			2.9			3.6
Change in tax assets and liabilities		4.0			(26.7	)		29.7			(102.4	)		2.2
Change in assets and liabilities		(6.3	)		(126.6	)		65.4			21.9			(80.1	)
Net cash provided by operating activities		235.3			133.6			312.9			179.0			60.4
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(49.7	)		(54.0	)		(55.1	)		(65.4	)		(68.2	)
Proceeds from sale of property, plant and equipment		—			1.7			—			—			—
Purchases of intangible assets		(60.7	)		(40.4	)		(45.5	)		(43.1	)		(41.5	)
Net cash used in investing activities		(110.4	)		(92.7	)		(100.6	)		(108.5	)		(109.7	)
CASH FLOWS FROM FINANCING ACTIVITIES
Capital repayment		—			(1,011.9	)		—			—			—
Purchase of shares in conjunction with conversion rights of bond holders and stock options		—			(203.6	)		(87.6	)		—			—
Dividend paid		—			—			—			(107.5	)		(0.4	)
Net proceeds from issuance of shares and stock options		25.4			11.5			3.0			0.6			1.4
Redemption and/or repayment of debt		(1.5	)		(7.9	)		—			—			(1.3	)
Net cash provided by (used in) financing activities		23.9			(1,211.9	)		(84.6	)		(106.9	)		(0.3	)
Net cash flows		148.8			(1,171.0	)		127.7			(36.4	)		(49.6	)
Effect of changes in exchange rates on cash		(2.8	)		(2.6	)		(2.2	)		0.2			1.7
Net increase (decrease) in cash & cash equivalents		146.0			(1,173.6	)		125.5			(36.2	)		(47.9	)

ASML — Notes to the Summary IFRS Consolidated Financial Statements

Basis of Presentation

ASML has prepared the accompanying summary consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the EU — accounting principles generally accepted in the Netherlands for companies quoted on Euronext Amsterdam. Further disclosures, as required under IFRS in annual reports and interim reporting (IAS 34), are not included. The accompanying consolidated financial statements are stated in thousands of euros (‘EUR’), except otherwise indicated.

For internal and external reporting purposes, ASML follows accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP is ASML’s primary accounting standard for the Company’s setting of financial and operational performance targets.

Principles of consolidation

The consolidated financial statements include the accounts of ASML Holding N.V. and all of its majority-owned subsidiaries. Subsidiaries are all entities over which ASML has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. All intercompany profits, balances and transactions have been eliminated in the consolidation.

Use of estimates

The preparation of ASML’s consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates and the reported amounts of revenue and expense during the reported periods. Actual results could differ from those estimates.

Recognition of revenues

ASML recognizes revenue when all four revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; seller’s price to the buyer is fixed or determinable; and collectibility is reasonably assured. At ASML, this policy generally results in revenue recognition from the sale of a system upon shipment. The revenue from the installation of a system is generally recognized upon completion of that installation at the customer site. Each system undergoes, prior to shipment, a “Factory Acceptance Test” in ASML’s clean room facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer. A system is shipped, and revenue recognized, only after all specifications are met and customer sign-off is received or waived. Although each system’s performance is re-tested upon installation at the customer’s site, ASML has never failed to successfully complete installation of a system at a customer’s premises.

For arrangements containing multiple elements, the revenue relating to the undelivered elements is deferred at estimated fair value until delivery of these elements. Revenue from installation services and service contracts provided to our customers is initially deferred and is recognized when the installation is completed and, in case of service contracts, over the life of those contracts. Revenue from extended and enhanced warranties is recognized in income on a straight-line basis over the contract period. The costs of providing services under extended and enhanced warranties are recognized when they occur.

ASML — Reconciliation U.S. GAAP — IFRS ^1,2

Net income

	Three months ended,						Nine months ended,
(in thousands EUR)	Sep 30, 2007			Sep 28, 2008			Sep 30, 2007			Sep 28, 2008
Net income under U.S. GAAP		166,279			73,294			478,460			410,394
Share-based payments (see Note 1)		280			(2,492	)		293			(3,009	)
Capitalization of development costs (see Note 2)		9,594			14,867			29,575			55,197
Convertible subordinated notes (see Note 3)		(2,265	)		—			(6,661	)		—
Income taxes (see Note 4)		—			(3,119	)		(7,648	)		(3,081	)
Net income under IFRS		173,888			82,550			494,019			459,501

Shareholders’ equity

	Sep 30,		Dec 31,		Mar 30,			Jun 29,			Sep 28,
(in thousands EUR)	2007		2007		2008			2008			2008
Shareholders’ equity under U.S. GAAP		1,831,438		1,890,948		1,958,159			2,060,575			2,122,848
Share-based payments (see Note 1)		7,126		787		(3,420	)		(3,266	)		(7,904	)
Capitalization of development costs (see Note 2)		120,344		138,424		157,900			176,818			193,780
Convertible subordinated notes (see Note 3)		2,894		—		—			—			—
Income taxes (see Note 4)		—		8,852		9,186			8,478			5,969
Shareholders’ equity under IFRS		1,961,802		2,039,011		2,121,825			2,242,605			2,314,693

Notes to the reconciliation from U.S. GAAP to IFRS

Note 1 Share-based Payments

Under IFRS, ASML applies IFRS 2, “Share-based Payments” beginning from January 1, 2004. In accordance with IFRS 2, ASML records as an expense the fair value of its share-based payments with respect to stock options granted to its employees after November 7, 2002.

Under U.S. GAAP, ASML applies SFAS No. 123(R) “Share-Based Payment” which is a revision of SFAS No.123. SFAS 123(R) requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant-date fair value of those instruments.

Note 2 Capitalization of development costs

Under IFRS, ASML applies IAS 38, “Intangible Assets”. In accordance with IAS 38, capitalized development expenditures are amortized over the expected useful life of the related product generally ranging between 2 and 3 years. Amortization starts when the developed product is ready for volume production.

Under U.S. GAAP, ASML applies SFAS No. 2, “Accounting for Research and Development Costs”. In accordance with SFAS No. 2, ASML charges costs relating to research and development to operating expense as incurred.

Note 3 Convertible Subordinated Notes

Under IFRS, ASML applies IAS 32 “Financial instruments: Disclosure and presentation” and IAS 39 “Financial instruments: Recognition and measurement” beginning from January 1, 2005. In accordance with IAS 32 and IAS 39, ASML accounts separately for the equity and liability component of its convertible notes (“Split accounting”). The equity component relates to the grant of a conversion option to shares to the holder of the bond. Split accounting results in additional interest charges.

Under U.S. GAAP, ASML accounts for its convertible bonds as a liability at the principal amount outstanding. As of December 31, 2007 ASML has no Convertible Subordinated Notes outstanding.

Note 4 Income taxes

Under IFRS, ASML applies IAS 12, “Income Taxes” beginning from January 1, 2005. In accordance with IAS 12, unrealized net income resulting from intercompany transactions that is eliminated from the carrying amount of assets on consolidation gives rise to a temporary difference for which deferred taxes must be recognized on consolidation. The deferred taxes are calculated based on the tax rate applicable in the purchaser’s tax jurisdiction.

Under U.S. GAAP, the elimination of unrealized net income from intercompany transactions that are eliminated from the carrying amount of assets on consolidation, give rise to a temporary difference for which prepaid taxes must be recognized on consolidation. Contrary to IFRS, the prepaid taxes under U.S. GAAP are calculated based on the tax rate applicable in the seller’s tax jurisdiction.

“Safe Harbor” Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, realization of backlog, IC unit demand, financial results, average sales price, gross margin and expenses. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, credit market deterioration on consumer confidence which could affect our customers, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), competitive products and pricing, manufacturing efficiencies, new product development and customer acceptance of new products, ability to enforce patents and protect intellectual property rights, the outcome of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission.

1

All quarterly information in this press release is unaudited.

2

In anticipation of endorsement by the European Union in Q4 2008, ASML has early adopted IFRIC 13 “Customer Loyalty Programmes” as of January 1, 2008. IFRIC 13 requires award credits offered to its customers as part of a volume purchase agreement to be accounted for using the deferred revenue model. Until December 31, 2007 cost accrual method was used. ASML early adopted this interpretation because the deferred revenue model better reflects the business rationale for offering award credits. Comparative figures for 2007 were adjusted to reflect this change in accounting policy. The impact of this change on equity as per January 1, 2007 amounted to EUR 8.1 million (decrease) and on net income for the year 2007 and the first quarter of 2008 amounted to EUR 8.6 million (decrease) and EUR 0.1 million (increase) respectively.